Health Care Fund

LHCVX

Track this Fund

Add to Hypo Tool

Daily price w/o sales charge as of 01/20/2021

$21.23

$0.06

YTD Returns w/o sales charge as of 01/20/2021

7.55%

Click here to view all legal text including risk information

Summary

What is the Health Care Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.

Fund Basicsas of 12/31/2020

Total Net Assets: $6.30 M
Inception Date: 08/01/2019
Dividend Frequency: Monthly (Daily Accrual)
Fund Gross Expense Ratio: 8.67%
Fund Net Expense Ratio: 0.70%
Number of Holdings: 90

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

	YTD	1-YR	3-YR	5-YR	10-YR	Since Inception 07/31/2019

w/o sales charge	37.57%	37.57%	-	-	-	32.24%
Lipper Category Avg. Health/Biotechnology Funds	27.48%	27.48%	-	-	-	-
MSCI ACWI Health Care Index (Net)	14.87%	14.87%	-	-	-	20.49%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

	YTD	1-YR	3-YR	5-YR	10-YR	Since Inception 07/31/2019

w/o sales charge	37.57%	37.57%	-	-	-	32.24%
Lipper Category Avg. Health/Biotechnology Funds	27.48%	27.48%	-	-	-	-
MSCI ACWI Health Care Index (Net)	14.87%	14.87%	-	-	-	20.49%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.

Returns with sales charge reflect a maximum sales charge of 5.75%

INVESTMENT TEAM

Devesh Karandikar

Portfolio Manager & Research Analyst

25 Years of Industry Experience

Matthew R. DeCicco, CFA

Partner & Director of Equities

21 Years of Industry Experience

Supported By 19 Investment Professionals with 34 Years Avg. Industry Experience

Contact a Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

	YTD	1-YR	3-YR	5-YR	10-YR	Since Inception 07/31/2019

w/o sales charge	37.57%	37.57%	-	-	-	32.24%
Lipper Category Avg. Health/Biotechnology Funds	27.48%	27.48%	-	-	-	-
MSCI ACWI Health Care Index (Net)	14.87%	14.87%	-	-	-	20.49%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

	YTD	1-YR	3-YR	5-YR	10-YR	Since Inception 07/31/2019

w/o sales charge	37.57%	37.57%	-	-	-	32.24%
Lipper Category Avg. Health/Biotechnology Funds	27.48%	27.48%	-	-	-	-
MSCI ACWI Health Care Index (Net)	14.87%	14.87%	-	-	-	20.49%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Year	Fund Returns	MSCI ACWI Health Care Index (Net)

2020	37.57%	14.87%
2019	8.07%	22.67%

Year	Q1	Q2	Q3	Q4	Yearly Returns

2021	-	-	-	-	7.55%
2020	-11.30%	21.57%	11.79%	14.11%	37.57%
2019	-	-	-	16.29%	8.07%

NAV Historical Prices

Date	Net Asset Value

Portfolio

Portfolio Positioning as of 06/30/2020

Portfolio Details as of 12/31/2020

Total Net Assets: $6.30 M
Number of Holdings: 90
Weighted Average Market Cap.: 64.9 B
P/B Ratio: 7.4x
P/E Ratio: 28.1x

To view definitions for the above Portfolio Details, Click here.

Holding	Sector	Assets

UnitedHealth Group, Inc.	Health Care	3.7%
Abbott Laboratories	Health Care	3.6%
Danaher Corp.	Health Care	2.9%
Novo Nordisk A/S	Health Care	2.6%
Thermo Fisher Scientific, Inc.	Health Care	2.6%
Vertex Pharmaceuticals, Inc.	Health Care	2.2%
Merck & Co., Inc.	Health Care	2.0%
Amgen Inc	Health Care	1.9%
Intuitive Surgical, Inc.	Health Care	1.9%
AstraZeneca plc	Health Care	1.8%

% of Total Assets		25.0%

Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.

Holding	Sector	Assets

UnitedHealth Group, Inc.	Health Care	4.1%
Thermo Fisher Scientific, Inc.	Health Care	3.0%
Abbott Laboratories	Health Care	2.9%
Novo Nordisk A/S	Health Care	2.9%
Danaher Corp.	Health Care	2.8%
Merck & Co., Inc.	Health Care	2.2%
AstraZeneca plc	Health Care	2.2%
Vertex Pharmaceuticals, Inc.	Health Care	2.1%
Intuitive Surgical, Inc.	Health Care	1.9%
Zoetis, Inc.	Health Care	1.9%
Amgen, Inc.	Health Care	1.8%
IDEXX Laboratories, Inc.	Health Care	1.8%
Lonza Group AG	Health Care	1.7%
Align Technology, Inc.	Health Care	1.5%
Zimmer Biomet Holdings, Inc.	Health Care	1.5%
Natera, Inc.	Health Care	1.4%
Genmab A/S	Health Care	1.4%
Insulet Corp.	Health Care	1.4%
CVS Caremark Corp.	Health Care	1.3%
Trillium Therapeutics Inc	Health Care	1.2%
Horizon Pharma plc	Health Care	1.2%
Edwards Lifesciences Corp.	Health Care	1.2%
Mirati Therapeutics, Inc.	Health Care	1.2%
BioNTech SE	Health Care	1.2%
Iovance Biotherapeutics Inc	Health Care	1.2%
Johnson & Johnson, Inc.	Health Care	1.2%
Chewy Inc	Consumer Discretionary	1.2%
Veeva Systems, Inc.	Health Care	1.1%
Teladoc Health	Health Care	1.1%
DexCom, Inc.	Health Care	1.1%
Cooper Cos., Inc.	Health Care	1.1%
HCA Holdings, Inc.	Health Care	1.1%
Bio-Rad Laboratories, Inc.	Health Care	1.1%
Seattle Genetics, Inc.	Health Care	1.0%
Twist Bioscience Corp	Health Care	1.0%
Insmed, Inc.	Health Care	1.0%
UCB SA	Health Care	1.0%
Boston Scientific Corp.	Health Care	1.0%
Nevro Corp.	Health Care	1.0%
Roche Holding Ltd. AG	Health Care	1.0%
Alcon Inc	Health Care	1.0%
Guardant Health Inc	Health Care	1.0%
10X Genomics Inc	Health Care	1.0%
Turning Point Therapeutics Inc	Health Care	1.0%
Schrodinger Inc/United States	Health Care	0.9%
Argenx SE	Health Care	0.9%
Sartorius Stedim Biotech	Health Care	0.9%
Bridgebio Pharma Inc	Health Care	0.8%
Acceleron Pharma, Inc.	Health Care	0.8%
Repligen Corp.	Health Care	0.8%
Inspire Medical Systems Inc	Health Care	0.8%
Quanterix Corp	Health Care	0.8%
Federal Home Loan Mortgage Corp.	Health Care	0.8%
Catalent Inc	Health Care	0.8%
Stoke Therapeutics Inc	Health Care	0.8%
Axonics Modulation Technologies Inc	Health Care	0.8%
Charles River Laboratories International, Inc.	Health Care	0.8%
Krystal Biotech Inc	Health Care	0.7%
TG Therapeutics, Inc.	Health Care	0.7%
Inari Medical Inc	Health Care	0.7%
West Pharmaceutical Services, Inc.	Health Care	0.7%
Constellation Pharmaceuticals Inc	Health Care	0.7%
Penumbra, Inc.	Health Care	0.7%
Arena Pharmaceuticals, Inc.	Health Care	0.7%
Pacific Biosciences of California, Inc.	Health Care	0.7%
Wuxi Biologics Cayman Inc	Health Care	0.7%
Blueprint Medicines Corp.	Health Care	0.7%
Berkeley Lights Inc	Health Care	0.7%
Sanofi	Health Care	0.7%
Sarepta Therapeutics, Inc.	Health Care	0.7%
Outset Medical Inc	Health Care	0.7%
CRISPR Therapeutics AG	Health Care	0.7%
SpringWorks Therapeutics Inc	Health Care	0.6%
Adaptive Biotechnologies Corp	Health Care	0.6%
M3 Inc	Health Care	0.6%
GW Pharmaceuticals plc	Health Care	0.6%
Zai Lab Ltd	Health Care	0.6%
Karuna Therapeutics Inc	Health Care	0.6%
Codexis Inc	Health Care	0.5%
ChemoCentryx Inc	Health Care	0.5%
Rocket Pharmaceuticals Inc	Health Care	0.5%
I-Mab	Health Care	0.5%
Silk Road Medical Inc	Health Care	0.5%
Tandem Diabetes Care, Inc.	Health Care	0.4%
Coherus Biosciences, Inc.	Health Care	0.4%
Black Diamond Therapeutics Inc	Health Care	0.4%
Tecan Group AG	Health Care	0.4%
Allogene Therapeutics Inc	Health Care	0.4%
Morphosys AG	Health Care	0.3%
Maravai LifeSciences Holdings Inc	Health Care	0.2%
NuVasive, Inc.	Health Care	0.2%

Attribution Analysis

for

Health Care Fund			Benchmark		Variance
Sector	Avg. Weight	Base Return	Avg. Weight	Base Return	Stock Selection	Group Weight	Total

The total base return displayed for the Fund does not capture daily cash flow and trading activity and therefore is subject to reasonable variance from the Fund's actual return. Please refer to Lord Abbett International Core Fund Performance Results for the Fund's longer-term returns. The Fund is actively managed and portfolio characteristics, such as individual holdings and sector weightings, may change significantly over time.

Please see "About Wilshire Attribution" of the performance attribution displayed above by Click here.

About Wilshire Attribution

The Wilshire Atlas Variance Analysis tool provides a methodology for explaining the difference in performance between a portfolio and its benchmark, based on the decomposition of returns. The user specifies the portfolio, index, link frequency, sector and weighting. The weighting can be shown as beginning, average or end weights and is used for display purposes only.

Average Weight (Portfolio): This is the average weight of each group in the portfolio. Alternatively, the weight at the end of the reporting period, or on average across the reporting period, may be selected.

Base Return (Portfolio): This is the weighted average holding period return for the securities in each group. This weighted average is calculated for each link period using beginning weights and then the resulting values are linked together to calculate the displayed value.

Average Weight (Benchmark): This is the average weight of each group in the benchmark. Alternatively, the weight at the end of the reporting period, or on average across the reporting period, may be selected.

Base Return (Benchmark): This is the weighted average holding period return for the benchmark securities in each group. This weighted average is calculated for each link period using beginning weights, then the resulting values are linked together to calculate the displayed value.

Stock Selection Variance: This is the success of selection decisions within each group versus the benchmark. It is calculated for each link period using the following equation: Stock Selection Variance = WP,G * (RP,G - RB,G), where WP,G = Weight of the group in the portfolio, RP,G = Return of the group in the portfolio, RB,G = Return of the group in the benchmark.

Group Weighting Variance: This is the result of weighting decisions in each group versus the benchmark. It is calculated for each link period using the following equation: Group Weighting Variance = (WP,G – WB,G) * (RB,G – RB,T), where WP,G = Weight of the group in the portfolio, WB,G = Weight of the group in the benchmark, RB,G = Return of the group in the benchmark, RB,T = Overall return of the benchmark.

Total Variance: This is the sum of group weighting and stock selection variances. This represents the amount of total variance that is explained by the selection and allocation decisions for each group.

Wilshire generated returns are calculated gross of fees based on end of day prices and do not capture intraday cash flow, price changes or trading activity, and therefore are subject to some variance from Lord Abbett returns. In addition, Wilshire and Lord Abbett may use different pricing sources and methodologies.

Not Classified securities represent those securities which have not been assigned an official GICS Direct classification. GICS Direct, a joint product of Standard & Poor’s and MSCI, provides industry classifications for more than 40,000 companies and over 45,000 securities. Not Classified securities may include, but are not limited to: Exchange-Traded Funds (ETFs), pink sheet-listed issues, pre-IPO placements, private placements, secondary issues, open-end funds, closed-end funds, and non-operating establishments.

Under certain circumstances, Lord Abbett may elect to have Wilshire map an ETF holding to the relevant characteristics represented by that ETF’s underlying index in order to reflect the exposure and performance contributed by the ETF to the overall portfolio. When this option is selected, Wilshire will remove the ETF from the Not Classified category and instead allocate the ETF’s exposures across the relevant attributes based on the composition of the ETF’s underlying index.

Source: Wilshire Attribution Software. GICS sector classification; non-GICS securities classified by Lord Abbett. Sectors may include many industries.

Contributors & Detractors as of 12/31/2020

Contributors

Holding	Contribution
Twist Bioscience Corp	0.8%
Pacific Biosciences	0.8%
Myokardia Inc	0.6%
Chewy Inc	0.6%
Tg Therapeutics Inc	0.6%

Detractors

Holding	Contribution
Vertex Pharmaceutica	-0.4%
Amgen, Inc.	-0.2%
AstraZeneca plc	-0.2%
Dexcom, Inc.	-0.2%
Emergent Biosolution	-0.1%

Fees & Expenses

Expense Ratioas of 12/31/2020

Fund Gross Expense Ratio	Fund Net Expense Ratio
8.67%	0.70%

Expense ratio details, Click here.

The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2021. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.

Fund Documents

Download fund documents & literature, create email subscriptions, and place direct mail order

	0Documents selected				Order
n/a	Portfolio Holdings 1Q Publish Date:11/03/2015
n/a	Portfolio Holdings 3Q Publish Date:11/03/2015
	Summary Prospectus Publish Date:11/03/2015
n/a	Statutory Prospectus Publish Date:11/03/2015
n/a	Prospectus (XBRL) Publish Date:11/03/2015
	SAI Publish Date:11/03/2015
	Annual Report Publish Date:11/03/2015
	Semi-Annual Report Publish Date:11/03/2015
	Fact Sheet Publish Date:11/03/2015
	Commentary Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

	Quantity Quantity	Remove Remove

Proceed to Checkout

(3 items)

View all forms & documents

IMPORTANT INFORMATION

A Note About Risk: The value of investments in equity securities will fluctuate in response to general economic conditions and to changes in the prospects of particular companies, including market, liquidity, currency, and political risks. Because the Fund invests a significant portion of its assets in securities issued by health care-related companies, developments affecting the health care industry will likely have a disproportionate impact on the Fund. The Fund engages in active and frequent trading of its securities, which may result in increased transaction fees, reduced investment performance, and higher taxes. The Fund may invest in foreign or emerging market securities, which may be adversely affected by economic, political, or regulatory factors and subject to currency volatility and greater liquidity risk. The Fund may invest in derivatives, which are subject to greater liquidity, leverage, and counterparty risk. These factors can affect Fund performance. The fund performance history at this time is very limited; therefore, performance achieved during its initial period of investment operation may not be replicated over longer periods and may not be indicative of how the Fund will perform in the future.

Performance data quoted is historical. Past performance is not indicative of future results. Current performance may be higher or lower than the performance quoted. The investment return and principal value of an investment in the Fund will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than their original cost. To obtain performance data current to the most recent quarter-end, go to quarter ending performance on our Website or call Lord Abbett at (888) 522-2388.

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by Standard & Poor’s Financial Services, LLC, and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, © 2011 American Bankers Association. “CUSIP” is a registered trademark of the American Bankers Association.

The MSCI ACWI Health Care Index includes large and mid cap securities across 23 Developed Markets (DM) and 26 Emerging Markets (EM) countries*. All securities in the index are classified in the Health Care as per the Global Industry Classification Standard

Indexes reflect total return, unless otherwise specified, with all dividends reinvested. Indexes are unmanaged, do not reflect the deduction of fees or expenses, and are not available for direct investment.

Fund Expense Ratio Detail: Reflects expenses for the Fund's fiscal year-end and is subject to change. Fund expenses may fluctuate with market volatility. A substantial reduction in Fund assets (since its most recently completed fiscal year), whether caused by market conditions or significant redemptions or both, will likely cause total operating expenses (as a percentage of Fund assets) to become higher than those shown.

Fund finder

Securing a sustainable future forour clients, our people, and our world. Inspired by our mission, we are committed to creating long-term financial security for our clients, empowering our people, advancing our communities, and ensuring a vibrant future for our planet.

Awards & Accolades

Error!

Error!

Error!

Tracked Funds

Quick Links

Pending Orders

LOG IN TO CONTINUE

LOG IN

QUICK LINKS

window.LAData = window.LAData || {}; window.LAData['react-retailMobileNavigation'] = { containerType: 'RetailMobileNavigation', };

Financial Professional

Verify Your Email Address

I have not received my verification email.

I'm still having trouble

REGISTER AT LORDABBETT.COM

FORGOT YOUR LORDABBETT.COM PASSWORD?

Financial Professionals

Forgot Password

Thank you.

Financial Professional*

ACCESS OTHER ACCOUNTS

Individual Investors

Small Business Plan Sponsors

Reset Your Password

Financial Professionals*

Confirmation Message

Share

Summary

Summary

What is the Health Care Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.

Fund Basicsas of 12/31/2020

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

INVESTMENT TEAM

Contact a Representative

Performance

Performance

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

Fund Expense Ratio :

Gross 8.67%

Net 0.70%

NAV Historical Prices

Portfolio

Portfolio

Portfolio Positioning as of 06/30/2020

Portfolio Details as of 12/31/2020

Attribution Analysis

Contributors & Detractors as of 12/31/2020

Contributors

Detractors

Fees & Expenses

Fees & Expenses

Expense Ratioas of 12/31/2020

Fund Documents

Fund Documents

Coming Soon.......

Please confirm your literature shipping address

Current Literature Shipping Address

Securing a sustainable future for
our clients, our people, and our world.

Inspired by our mission, we are committed to creating long-term financial security for our clients, empowering our people, advancing our communities, and ensuring a vibrant future for our planet.